Dynavax

$4.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.19%) Today

+$0.04 (+0.96%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Dynavax and other stocks, options, and ETFs commission-free!

About DVAX

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA. The listed name for DVAX is Dynavax Technologies Corporation Common Stock.

CEO

Ryan Spencer

Employees

231

Headquarters

Emeryville, California

Founded

1996

Market Cap

457.22M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

3.23M

High Today

$4.28

Low Today

$4.06

Open Price

$4.20

Volume

2.00M

52 Week High

$12.44

52 Week Low

$1.80

Collections

DVAX Earnings

-$0.65

-$0.43

-$0.22

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 10, After Hours